Monitor upcoming FDA interactions in 2026 that could shape Phase 3 trial design; watch for initiation of Phase 3 dosing in Q1 2027 as a key catalyst. Despite higher losses, robust cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
Upstream Bio reported Q4 and full-year 2025 financial results, highlighted by a strong cash position of $341.5 million and advancement of its Phase 2 programs for verekitug in severe asthma and CRSwNP. Positive top-line data from the Phase 2 VALIANT trial showed significant reductions in asthma exacerbations, supporting plans to initiate Phase 3 trials in both indications in Q1 2027.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and short-term investments totaled $341.5 million as of December 31, 2025, sufficient to fund operations through 2027.
- Phase 2 VALIANT trial in severe asthma met primary endpoint with 56% reduction in annualized asthma exacerbation rate (AAER) at 100 mg every 12 weeks (p<0.0003).
- Phase 2 VIBRANT trial in CRSwNP showed placebo-adjusted NPS reduction of -1.95 (p<0.0001) in WOCF analysis.
- Research and development expenses increased to $40.2M in Q4 2025 from $21.8M in Q4 2024 due to clinical and manufacturing costs.
- Net loss widened to $42.5M in Q4 2025 from $21.2M in Q4 2024.
Financial Impact
Increased R&D spend by $18.4M YoY in Q4, driven by verekitug development; net loss doubled to $42.5M despite strong cash reserves.
Risk Factors
- Clinical development risk: Phase 3 success not guaranteed despite positive Phase 2 data.
- Increased burn rate may pressure cash runway if development timelines extend beyond 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262866 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 8w ago | 8-K | $6.55 | awaiting T+60 | awaiting T+60 | $2.79 (−57.40%) |
Aug 11, 2026 11w ago | 8-K | $7.44 | awaiting T+60 | awaiting T+60 | $2.79 (−62.50%) |
Jun 17, 2026 18w ago | Insider Cluster | $6.25 | awaiting T+60 | awaiting T+60 | $2.79 (−55.36%) |
Jun 14, 2026 19w ago | Press Release | $6.10 $5.96 | ▼ −2.30% | ▼ −3.30% | $2.79 (−54.26%) |
May 18, 2026 23w ago | Press Release | $8.51 $6.91 | ▼ −18.80% | ▼ −23.65% | $2.79 (−67.22%) |
May 13, 2026 23w ago | Press Release | $9.36 $7.25 | ▲ +22.54% | ▲ +26.98% | $2.79 (+70.19%) |
Apr 17, 2026 27w ago | Press Release | $9.99 $7.14 | ▼ −28.53% | ▼ −34.67% | $2.79 (−72.07%) |
Mar 26, 2026 30w ago | 424B5 | $8.67 $6.41 | ▲ +26.07% | ▲ +42.13% | $2.79 (+67.82%) |
Mar 26, 2026 30w ago | Press Release | $9.79 $6.40 | ▼ −34.68% | ▼ −48.63% | $2.79 (−71.50%) |
Mar 16, 2026 32w ago | Insider Cluster | $9.61 $6.45 | ▼ −32.88% | ▼ −43.37% | $2.79 (−70.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers